Pharmacy News

Uptake of newer diabetes products dominate trends in U.S. adults with diabetes

New research published in JAMA Network Open finds that insulin glargine and other insulin analogs are the most-used forms of insulin in the United States, alongside pen devices as a delivery method.

The findings were derived from the Health National Disease and Therapeutic Index, which includes diagnostic and prescribing information for patients being treated by office-based physicians.

According to the study data, there were a total of 27,860,691 insulin treatment visits for type 2 diabetes from 2016 to 2020. Long-acting analog insulins were indicated in 67.3% of such visits in 2016, and 74.8% of them in 2020. Meanwhile, rapid-acting insulin analogs accounted for 21.2% of insulin-related treatment visits in 2016 and 16.5% in 2020. Intermediate-and short-acting human insulins made up only 3.7% of such visits in 2016 and 2.6% in 2020.

Together, analog insulins accounted for 92.7% and 86.3% of insulin treatment visits in 2016 and 2020, respectively, while the human insulins accounted for just 3.7% of such visits in 2016, and 2.6% in 2020. Biosimilar analog insulins first appeared in the Health National Disease and Therapeutic Index in 2017, and represented 2.6% of visits that year and 8.2% by 2020. The proportion of treatment visits for insulin vials/syringes declined from 63.9% in 2016 to 41.1% in 2020, while visits for insulin pens increased from 36.1% to 58.7%.




Previous Article Opioid taper and overdose risk: What pharmacists should know
Next Article HPV vaccination program yields positive results on cervical cancer reduction in England
26599 Rate this article:
No rating
Please login or register to post comments.